How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
37
VNDA Quote, Financials, Valuation and Earnings
Last price:
$4.81
Seasonality move
:
-2.27%
Day range:
$4.65 - $4.83
52-week range:
$3.46 - $6.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.47x
P/B ratio:
0.52x
Volume:
292.9K
Avg. volume:
669.7K
1-year change:
21.66%
Market cap:
$281.6M
Revenue:
$192.6M
EPS (TTM):
-$0.28
Analysts' Opinion
-
Consensus RatingVanda Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.17, Vanda Pharmaceuticals has an estimated upside of 151.9% from its current price of $4.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.50 representing -13.87% downside risk from its current price of $4.83.
Fair Value
-
According to the consensus of 2 analysts, Vanda Pharmaceuticals has 151.9% upside to fair value with a price target of $12.17 per share.
VNDA vs. S&P 500
-
Over the past 5 trading days, Vanda Pharmaceuticals has underperformed the S&P 500 by -0.81% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vanda Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vanda Pharmaceuticals has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Vanda Pharmaceuticals reported revenues of $47.7M.
Earnings Growth
-
Vanda Pharmaceuticals earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Vanda Pharmaceuticals reported earnings per share of -$0.09.
Enterprise value:
-94.6M
EV / Invested capital:
-0.17x
Price / LTM sales:
1.47x
EV / EBIT:
--
EV / Revenue:
-0.50x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$178.7M
Return On Assets:
-2.53%
Net Income Margin (TTM):
-8.59%
Return On Equity:
-3.02%
Return On Invested Capital:
-3.02%
Operating Margin:
-23.09%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $257.9M | $211.9M | $190.9M | $38.8M | $47.7M | |
| Gross Profit | $233.6M | $194.3M | $178.7M | $35.8M | $45.1M | |
| Operating Income | $8.3M | -$229K | -$37.5M | -$6M | -$11M | |
| EBITDA | $11.1M | $2.3M | -$30.2M | -$5.4M | -$9M | |
| Diluted EPS | $0.12 | $0.21 | -$0.28 | $0.00 | -$0.09 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $389.5M | $461.8M | $507.1M | $536.6M | $432.4M | |
| Total Assets | $515.9M | $579.8M | $621.8M | $641.6M | $645.1M | |
| Current Liabilities | $61.4M | $72M | $92.6M | $84.8M | $89.1M | |
| Total Liabilities | $75.3M | $86.4M | $106.1M | $98.5M | $103.9M | |
| Total Equity | $440.6M | $493.3M | $515.7M | $543.1M | $541.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $49.2M | $25.9M | -$17.7M | -$2.1M | -$14.6M | |
| Cash From Investing | -$51.5M | $107.2M | -$65.2M | $35.3M | $12.1M | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | $48.6M | $25.6M | -$18.2M | -$2.1M | -$14.7M | |
VNDA
Sector
Market Cap
$281.6M
$46.1M
Price % of 52-Week High
71.56%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
21.66%
-30.52%
Beta (5-Year)
0.757
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.68
200-day SMA
Sell
Level
$5.03
Bollinger Bands (100)
Sell
Level
4.64 - 5.2
Chaikin Money Flow
Sell
Level
-146.1M
20-day SMA
Buy
Level
$4.79
Relative Strength Index (RSI14)
Buy
Level
51.42
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-24
50-day SMA
Sell
Level
$4.86
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
63.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9366)
Buy
CA Score
(Annual)
Level (1.0961)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.3414)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Stock Forecast FAQ
In the current month, VNDA has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VNDA average analyst price target in the past 3 months is $12.17.
-
Where Will Vanda Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vanda Pharmaceuticals share price will rise to $12.17 per share over the next 12 months.
-
What Do Analysts Say About Vanda Pharmaceuticals?
Analysts are divided on their view about Vanda Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vanda Pharmaceuticals is a Sell and believe this share price will drop from its current level to $5.50.
-
What Is Vanda Pharmaceuticals's Price Target?
The price target for Vanda Pharmaceuticals over the next 1-year time period is forecast to be $12.17 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VNDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vanda Pharmaceuticals is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of VNDA?
You can purchase shares of Vanda Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vanda Pharmaceuticals shares.
-
What Is The Vanda Pharmaceuticals Share Price Today?
Vanda Pharmaceuticals was last trading at $4.81 per share. This represents the most recent stock quote for Vanda Pharmaceuticals. Yesterday, Vanda Pharmaceuticals closed at $4.83 per share.
-
How To Buy Vanda Pharmaceuticals Stock Online?
In order to purchase Vanda Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
